Observational studyClinical endocrinology2026
Adrenal Insufficiency During Treatment With Immune-Checkpoint Inhibitors: How to Simplify the Diagnostic Pathway?
Observational study in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adrenal Insufficiency During Treatment With Immune-Checkpoint Inhibitors: How to Simplify the Diagnostic Pathway?Clinical endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
OBJECTIVE AND
backgroundEarly identification of adrenal insufficiency (AI) during immune-checkpoint inhibitors (ICIs) is crucial to prevent life-threatening consequences; however, the diagnosis is challenging. DESIGN, PATIENTS AND MEASUREMENT: In this prospective observational study, ICI-treated cancer patients with morning serum cortisol (SC) within the grey zone (83-414 nmol/L) were enroled. A low-dose adrenocorticotropic hormone (ACTH) stimulation test was performed to assess peak stimulated SC, preceded by re-evaluation of morning SC. The analysis aimed to refine morning SC cut-offs to minimize the diagnostic grey zone reducing the need for ACTH stimulation. To interpret the results of ACTH test, it was employed both the threshold for peak stimulated SC provided by the Endocrine Society guidelines (500 nmol/L) and an assay-specific cut-off for the Abbott platform recently proposed in literature (414 nmol/L). Moreover, the utility of salivary cortisol and cortisone upon awakening was explored.
resultsIn 30 ICI-treated patients, a good positive correlation between morning and peak stimulated SC was confirmed (r = 0.72, p < 0.001); peak stimulated SC ≤ 500 nmol/L and ≤ 414 nmol/L was detected in 36.7% and 20% of subjects, respectively; all cases were secondary AI. ROC curve analysis identified optimal morning SC thresholds for AI prediction and exclusion (> 196 nmol/L and ≤ 397 nmol/L in case of pathological peak stimulated SC ≤ 500 nmol/L; > 163 nmol/L and ≤ 251 nmol/L in case of pathological peak stimulated SC ≤ 414 nmol/L). Salivary cortisol and cortisone upon awakening positively correlated with peak stimulated SC (r = 0.49 and r = 0.56, respectively, p < 0.01).
conclusionsMorning SC is a reliable tool for the screening of ICI-related AI; the need for dynamic stimulation would be reduced by the application of assay-specific cut-offs. Salivary hormone analysis of cortisol and cortisone upon awakening may represent a viable alternative in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.